Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

Open in Screener

ALNY

Alnylam Pharmaceuticals Inc

156.65

Nov 12 • 3:59 PM ET -3.20 (-2.00%)

158.80

Aftermarket • 7:44 PM ET +2.15 (1.37%)

Healthcare Biotechnology USA Large NASD

Peers: ARWR IONS BBIO REGN ARGX VRTX WVE BMRN NTLA AMGN

| Held by: VTI VO QQQ VUG VXF VOT IBB CGGR IWP QQQM

Index	NDX, RUI
Market Cap	20.98B
Enterprise Value	20.39B
Income	2.72B
Sales	5.01B
Book/sh	26.92
Cash/sh	26.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2500
IPO	May 28, 2004

P/E	7.91
Forward P/E	17.48
PEG	0.25
P/S	4.19
P/B	5.82
P/C	5.85
P/FCF	27.90
EV/EBITDA	19.74
EV/Sales	4.07
Quick Ratio	2.43
Current Ratio	2.48
Debt/Eq	0.83
LT Debt/Eq	0.64
Option/Short	Yes / Yes

EPS (ttm)	19.80
EPS next Y	8.96
EPS next Q	1.72
EPS this Y	690.54%
EPS next Y	-51.33%
EPS next 5Y	68.70%
EPS past 3/5Y	- -
Sales past 3/5Y	52.98% 49.77%
EPS Y/Y TTM	6459.20%
Sales Y/Y TTM	56.17%
EPS Q/Q	754.21%
Sales Q/Q	16.74%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	847.22% 1.92%

Insider Own	0.32%
Insider Trans	-0.48%
Inst Own	100.49%
Inst Trans	0.76%
ROA	42.41%
ROE	141.97%
ROIC	46.01%
Gross Margin	77.28%
Oper. Margin	19.50%
Profit Margin	54.34%
SMA20	-17.86%
SMA50	-29.19%
SMA200	-43.32%
Trades

Shs Outstand	133.88M
Shs Float	133.51M
Short Float	4.09%
Short Ratio	2.77
Short Interest	5.47M
52W High	479.79 -67.35%
52W Low	149.18 5.01%
Volatility	4.67% 5.07%
ATR (14)	10.39
RSI (14)	27.51
Beta	0.44
Rel Volume	1.78
Avg Volume	1.98M
Volume	3,516,268

Perf Week	-0.01%
Perf Month	-30.21%
Perf Quarter	-31.49%
Perf Half Y	-46.62%
Perf YTD	-60.61%
Perf Year	-65.40%
Perf 3Y	-3.24%
Perf 5Y	-8.32%
Perf 10Y	236.59%
Recom	1.71
Target Price	298.00
Prev Close	159.85
Price	156.65
Change %	-2.00%

Consensus

Buy

Avg. Price Target

$298.00

Implied Upside

+90.2%

Analysts15incl. previous ratings

Rating Distribution10 Buy · 5 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 02, 2026	Downgrade	TTruist	Buy → Hold	$225	+43.6%
Oct 30, 2026	Downgrade	RRaymond James	Strong Buy → Outperform	$315	+101.1%
Oct 30, 2026	Downgrade	BBernstein	Outperform → Mkt Perform	$199	+27.0%
Oct 29, 2026	Downgrade	SStifel	Buy → Hold	$225	+43.6%
Oct 15, 2026	Resumed	UUBS	Buy	$354	+126.0%
Aug 19, 2026	Initiated	BBMO Capital Markets	Outperform	$318	+103.0%
Aug 03, 2026	Upgrade	RRaymond James	Outperform → Strong Buy	$420	+168.1%
May 19, 2026	Initiated	CCitigroup	Buy	$380	+142.6%
Mar 16, 2026	Downgrade	JJefferies	Buy → Hold	$330	+110.7%
Jan 28, 2026	Resumed	BBarclays	Overweight	$527	+236.4%
Jan 07, 2026	Resumed	OOppenheimer	Outperform	$500	+219.2%
Aug 04, 2025	Upgrade	WWolfe Research	Underperform → Peer Perform
Aug 04, 2025	Upgrade	OOppenheimer	Perform → Outperform	$490	+212.8%
Jul 30, 2025	Resumed	RRaymond James	Outperform	$370	+136.2%
Jul 21, 2025	Initiated	TTruist	Buy	$385	+145.8%
Mar 31, 2025	Initiated	RRedburn Atlantic	Buy	$353	+125.3%
Mar 24, 2025	Upgrade	JJP Morgan	Neutral → Overweight	$280 → $328	+109.4%
Nov 12, 2024	Downgrade	WWolfe Research	Peer Perform → Underperform
Oct 16, 2024	Initiated	BScotiabank	Sector Outperform
Aug 16, 2024	Upgrade	GGoldman	Neutral → Buy	$198 → $370	+136.2%

Nov-10-26 09:00AM	Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD (Business Wire)
Nov-09-26 09:50AM	Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA (vutrisiran) in ATTR-CM (Business Wire)
Nov-06-26 08:13AM	Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down (BioPharma Dive)
Nov-04-26 04:15PM	Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership (Business Wire)
02:47PM	Tax-loss selling candidates: the worst-performing US large caps of 2026 (Investing.com)
07:00AM	Loading…
07:00AM	Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference (Business Wire)
Nov-03-26 08:30AM	Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA (vutrisiran) at AHA and ISA 2026 (Business Wire)
Nov-02-26 09:00AM	Earnings roundup: AstraZenecas cost cuts, Alnylams slump and Regenerons resilience (BioPharma Dive)
05:36AM	FDA Decision Watch: Regeneron And Roches Autoimmune Drugs, Capricors DMD Therapy In Spotlight (Stocktwits)
Oct-29-26 02:26PM	ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays (Stocktwits) -25.13%
10:07AM	Alnylam's Tax-Fueled EPS Blowout Masks A Slowing AMVUTTRA Launch And TTR Guidance Pinned To The Low End (Earnings Whispers)
08:14AM	Alnylam: Q3 Earnings Snapshot (Associated Press)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress (Business Wire)
Oct-23-26 03:45AM	Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntingtons Disease (Business Wire)
Oct-21-26 09:53AM	Alnylam Must Prove First-Line Amvutra Demand Can Carry A Reset TTR Outlook (Earnings Whispers)
10:19AM	Loading…
Oct-19-26 10:19AM	Why Merck KGaA Is Paying a 130% Premium For This Gene-Silencing Tech (Barrons.com)
Oct-18-26 11:15PM	Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In (Stocktwits)
Oct-16-26 10:44AM	What Is The Case For Waiting On Moderna Stock? (Trefis)
06:50AM	Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings (Investing.com)
06:33AM	Next-gen RNAi drugmaker City prices $200M IPO (BioPharma Dive)
Oct-15-26 08:00AM	Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results (Business Wire)
Oct-12-26 05:01PM	Where Could Moderna's Next Growth Come From? (Trefis)
Oct-09-26 11:36AM	Is Vertex Stock Worth More Than Its Competitors? (Trefis)
Sep-29-26 09:00AM	AMVUTTRA (vutrisiran) 'Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM (Business Wire)
Sep-24-26 08:36PM	RNAi drug specialist ADARx raises $446M IPO (BioPharma Dive)
Sep-22-26 01:39PM	Was Moderna Stock's Cancer Vaccine Run Visible In Advance? (Trefis)
Sep-15-26 11:18AM	Slate Medicines Names Kenneth Koblan as Chief Scientific Officer (Exec Edge)
Sep-02-26 08:00AM	Alnylam to Webcast Presentations at Upcoming September Investor Conferences (Business Wire) +8.65%
Aug-31-26 08:48AM	Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself (NYSE)
Aug-30-26 08:23AM	Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings (Business Wire)
05:18PM	Loading…
Aug-28-26 05:18PM	IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial Jefferies Sees Neutral To Negative Readthrough To ALNY (Stocktwits)
08:54AM	Alnylam stock drops on rival heart trial: Why analysts see core business safe (Investing.com)
06:58AM	AstraZeneca, Ionis data spark debate about RNA drugs impact on deadly heart disease (BioPharma Dive)
Aug-26-26 11:13AM	Moderna Stock Carries A Market Value Its Revenue Does Not Support (Trefis)
Aug-24-26 03:01PM	Moderna Stock Had A Readout Waiting In Plain Sight (Trefis)
08:33AM	Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 (Business Wire)
Aug-20-26 02:21PM	Moderna's Melanoma Result Landed On A Market Positioned The Other Way (Trefis) -5.49%
Aug-11-26 06:21AM	Drugs that missed the mark in pharmas last earnings round (Pharma Voice)
Aug-03-26 09:49AM	Starbucks upgraded, eBay downgraded: Wall Street's top analyst calls (The Fly) +7.21%
Jul-31-26 03:29PM	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? (Trefis)
Jul-30-26 05:04PM	Alnylam Pharmaceuticals Inc (ALNY) (Q2 2026) Earnings Call Highlights: Amvuttra Surpasses $1 ... (GuruFocus.com) -28.31%
12:12PM	Alnylam plunges as earnings deliver one-two punch (BioPharma Dive)
08:16AM	Alnylam: Q2 Earnings Snapshot (Associated Press)
08:00AM	Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress (Business Wire)
Jul-23-26 11:00AM	Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? (Trefis)
Jul-16-26 09:06AM	Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
08:00AM	Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results (Business Wire)
Jul-15-26 03:30AM	Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease (Business Wire)
Jul-13-26 09:12AM	What It Means To Hold Moderna Stock In A Crash (Trefis)
Jul-10-26 08:14AM	Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? (Trefis)
07:35AM	The Long Climb Back For Ionis Stock (Trefis)
Jul-09-26 10:38AM	AstraZeneca, Ionis Stocks Stumble After Heart Drug Fails Key Trial (The Wall Street Journal)
07:38AM	AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars. (Barrons.com)
07:14AM	AstraZeneca stock drops 9% after Wainua heart drug trial fails (Quartz)
Jul-08-26 08:48AM	Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
Jun-25-26 09:00AM	Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform (Business Wire)
Jun-12-26 09:00AM	Alnylam to Host Tenth RNAi Roundtable Webcast Series (Business Wire)
Jun-04-26 06:42AM	Alnylam, Inceptive ink AI deal potentially worth $2B (BioPharma Dive)
Jun-03-26 04:45PM	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics (Business Wire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-20-26 03:29PM	JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms (Investing.com)
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
08:30AM	Alnylam Issues 2025 Corporate Responsibility Report (Business Wire)
May-12-26 02:30AM	New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden (Business Wire)
May-07-26 08:00AM	Alnylam to Webcast Presentations at Upcoming Investor Conferences (Business Wire)
May-04-26 08:30AM	Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM (Business Wire)
Apr-30-26 09:15AM	Alnylam Pharma Surges After Sales Of Its Biggest Moneymaker Catapult (Investor's Business Daily)
08:09AM	Alnylam: Q1 Earnings Snapshot (Associated Press)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress (Business Wire)
Apr-16-26 08:00AM	Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results (Business Wire)
Apr-07-26 10:00AM	Nasdaq opens in red as Iran says 'restraint is ended' ahead of Trump deadline (Proactive)
09:49AM	FTSE 100 Live: Defence stocks lead decline as Trump's Iran deadline looms (Proactive)
Mar-30-26 01:00PM	New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management (Business Wire)
Mar-24-26 07:30AM	Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association (Business Wire)
Mar-16-26 09:37AM	Qualcomm, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Mar-10-26 02:49PM	BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz (Benzinga)
08:00AM	Alnylam to Webcast TTR Investor Webinar (Business Wire)
Mar-06-26 07:19AM	Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal (Pharmaceutical Technology)
05:13AM	Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs (BioPharma Dive)
Mar-05-26 01:35PM	Tenaya Therapeutics Stock Jumps After New Alnylam Deal (Benzinga)
Mar-04-26 06:57AM	Blackstone puts $400M into Teva, Sanofi gut disease drug (BioPharma Dive)
Mar-02-26 11:39PM	Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. (MarketBeat)
Mar-01-26 01:33AM	Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock (Insider Monkey)
Feb-24-26 11:43AM	GSK Strikes $1 Billion China RNA Deal (GuruFocus.com)
Feb-23-26 10:00AM	Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-20-26 04:08AM	Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge (Insider Monkey)
Feb-19-26 12:01AM	Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth (Insider Monkey)
Feb-17-26 12:09PM	RNA-targeting small molecules: a new frontier of drug discovery (Pharmaceutical Technology) +5.79%
Feb-14-26 01:21AM	Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? (Insider Monkey)
Feb-13-26 04:30PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +5.79%
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
Feb-12-26 04:06PM	Alnylam Pharmaceuticals Inc (ALNY) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
10:00AM	Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates (Zacks)
08:22AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Feb-11-26 12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
Feb-10-26 10:00AM	Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PYOTT DAVID E I	Director	Nov 10 '26	Option Exercise	71.99	3,780	272,122	5,362	Nov 12 04:07 PM
Sigal Charles Elliott	Director	Nov 10 '26	Buy	152.25	1,600	243,600	3,600	Nov 12 04:05 PM
SCHULMAN AMY W	Director	Nov 09 '26	Buy	156.82	1,910	299,526	25,959	Nov 12 04:01 PM
SUPRAN BRYAN	EVP, CLO and Secretary	Oct 02 '26	Sale	226.88	1,758	398,855	12,807	Oct 06 04:12 PM
SUPRAN BRYAN	Officer	Oct 02 '26	Proposed Sale	226.88	1,758	398,862		Oct 02 03:45 PM
PYOTT DAVID E I	Director	Jun 01 '26	Option Exercise	0.00	3,830	0	5,412	Jun 03 04:25 PM
PYOTT DAVID E I	Director	Jun 01 '26	Sale	299.18	3,830	1,145,853	1,582	Jun 03 04:25 PM
PYOTT DAVID E I	Director	Jun 01 '26	Proposed Sale	299.51	3,830	1,147,123		Jun 01 04:25 PM
SCHULMAN AMY W	Director	May 13 '26	Option Exercise	70.20	11,250	789,750	23,211	May 14 04:17 PM
McLaughlin Melissa	Chief Human Resources Officer	Apr 06 '26	Sale	330.42	2,286	755,329	9,443	Apr 07 04:21 PM
McLaughlin Melissa	Chief Human Resources Officer	Apr 02 '26	Sale	319.59	1,624	519,014	11,729	Apr 07 04:21 PM
McLaughlin Melissa	Officer	Apr 06 '26	Proposed Sale	320.10	2,286	731,749		Apr 06 04:05 PM
Garg Pushkal	EVP Chief R&D	Mar 05 '26	Sale	323.96	2,404	778,812	18,693	Mar 06 04:13 PM
Garg Pushkal	EVP Chief R&D	Mar 04 '26	Sale	323.08	2,309	745,984	21,097	Mar 06 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 04 '26	Sale	323.08	2,933	947,581	95,695	Mar 06 04:13 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 04 '26	Sale	323.08	2,468	797,351	61,805	Mar 06 04:12 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 04 '26	Sale	323.08	2,309	745,984	34,297	Mar 06 04:12 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 05 '26	Sale	323.98	658	213,177	20,569	Mar 06 04:11 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '26	Sale	323.08	633	204,508	21,227	Mar 06 04:11 PM
Fitzgerald Kevin Joseph	Officer	Mar 05 '26	Proposed Sale	323.69	658	212,988		Mar 05 04:04 PM
Garg Pushkal	Officer	Mar 05 '26	Proposed Sale	323.69	2,404	778,151		Mar 05 04:03 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 02 '26	Sale	327.65	2,206	722,801	64,273	Mar 04 07:31 PM
Garg Pushkal	EVP Chief R&D	Mar 03 '26	Sale	319.74	1,775	567,546	23,406	Mar 04 07:31 PM
Garg Pushkal	EVP Chief R&D	Mar 02 '26	Sale	327.66	1,717	562,585	25,181	Mar 04 07:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '26	Sale	319.73	1,652	528,189	21,860	Mar 04 07:30 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 02 '26	Sale	327.65	1,598	523,584	23,512	Mar 04 07:30 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 02 '26	Sale	327.65	1,598	523,584	36,606	Mar 04 07:30 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 02 '26	Sale	327.65	6,799	2,227,698	98,628	Mar 04 07:29 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '26	Proposed Sale	321.37	1,652	530,903		Mar 03 04:49 PM
Garg Pushkal	Officer	Mar 03 '26	Proposed Sale	321.37	1,775	570,432		Mar 03 04:11 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '26	Option Exercise	0.00	5,921	0	91,583	Mar 02 04:10 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '26	Option Exercise	0.00	1,908	0	61,710	Mar 02 04:09 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '26	Option Exercise	0.00	1,666	0	33,435	Mar 02 04:09 PM
Garg Pushkal	EVP Chief R&D	Feb 27 '26	Option Exercise	0.00	1,908	0	26,756	Mar 02 04:08 PM
Garg Pushkal	EVP Chief R&D	Feb 27 '26	Sale	331.34	4,627	1,533,100	22,129	Mar 02 04:08 PM
Garg Pushkal	Officer	Feb 27 '26	Proposed Sale	331.34	4,627	1,533,107		Feb 27 04:05 PM
Garg Pushkal	EVP Chief R&D	Feb 13 '26	Sale	310.08	2,242	695,201	24,848	Feb 17 07:28 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 13 '26	Sale	310.08	6,958	2,157,542	85,662	Feb 17 07:27 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 13 '26	Sale	310.08	1,959	607,448	31,769	Feb 17 07:27 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 17 '26	Sale	331.96	2,041	677,532	21,264	Feb 17 07:26 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 13 '26	Sale	310.08	1,959	607,448	23,305	Feb 17 07:26 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 13 '26	Sale	310.08	2,242	695,201	59,802	Feb 17 07:26 PM
Fitzgerald Kevin Joseph	Officer	Feb 17 '26	Proposed Sale	331.96	2,041	677,532		Feb 17 04:10 PM
Garg Pushkal	EVP Chief R&D	Jan 12 '26	Sale	362.87	1,510	547,929	22,511	Jan 14 04:23 PM
Greenstreet Yvonne	Chief Executive Officer	Jan 12 '26	Sale	362.86	9,577	3,475,157	78,411	Jan 14 04:23 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jan 12 '26	Sale	362.87	2,780	1,008,766	57,465	Jan 14 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jan 12 '26	Sale	362.87	1,510	547,927	29,728	Jan 14 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 13 '26	Sale	370.33	2,290	848,065	21,264	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 12 '26	Sale	362.87	1,510	547,927	23,554	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	Officer	Jan 13 '26	Proposed Sale	369.10	2,290	845,239		Jan 13 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '25	Option Exercise	106.40	4,697	499,756	70,106	Dec 01 04:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Option Exercise	119.13	8,161	972,220	33,392	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Sale	452.18	12,128	5,483,990	21,264	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	Officer	Nov 17 '25	Proposed Sale	449.00	12,128	5,445,472		Nov 17 04:04 PM

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

M.D.Dr. Yvonne L. Greenstreet M.B.A.

Co-FounderDr. Phillip A. Sharp Ph.D.

CFO & Executive VPMr. Jeffrey V. Poulton M.B.A.

Chief Legal OfficerMr. Bryan Andrew Supran J.D.

Executive VP & Chief Research & Development OfficerDr. Pushkal P. Garg M.D.

Open in Screener

ELV

Elevance Health Inc

429.90

Nov 12 • 3:59 PM ET +0.42 (0.10%)

429.90

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Healthcare Plans USA Large NYSE

ELV Elevance Health Inc daily Stock Chart

Peers: CI UNH HUM CNC CVS MOH OSCR ALHC CLOV HCA

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM SEQ SPYM

Index	S&P 500, RUI
Market Cap	92.88B
Enterprise Value	-
Income	5.14B
Sales	201.83B
Book/sh	206.75
Cash/sh	-
Dividend Est.	6.86 (1.60%)
Dividend TTM	6.87 (1.60%)
Dividend Ex-Date	Dec 04, 2026
Dividend Gr. 3/5Y	10.14% 12.47%
Payout	27.13%
Employees	97100
IPO	Oct 30, 2001

P/E	18.33
Forward P/E	14.21
PEG	3.12
P/S	0.46
P/B	2.08
P/C	-
P/FCF	14.26
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	1.47
Debt/Eq	0.69
LT Debt/Eq	0.68
Option/Short	Yes / Yes

EPS (ttm)	23.46
EPS next Y	30.25
EPS next Q	2.08
EPS this Y	-4.09%
EPS next Y	4.12%
EPS next 5Y	4.55%
EPS past 3/5Y	1.27% 6.99%
Sales past 3/5Y	8.34% 10.32%
EPS Y/Y TTM	-4.06%
Sales Y/Y TTM	3.60%
EPS Q/Q	18.02%
Sales Q/Q	1.42%
Earnings	Oct 21 BMO
EPS/Sales Surpr.	48.28% 2.35%

Insider Own	0.23%
Insider Trans	-2.01%
Inst Own	95.41%
Inst Trans	-0.37%
ROA	4.10%
ROE	11.60%
ROIC	6.85%
Gross Margin	-
Oper. Margin	3.81%
Profit Margin	2.55%
SMA20	0.52%
SMA50	3.57%
SMA200	14.61%
Trades

Shs Outstand	216.11M
Shs Float	215.55M
Short Float	2.11%
Short Ratio	3.76
Short Interest	4.54M
52W High	450.69 -4.61%
52W Low	274.84 56.42%
Volatility	2.35% 3.01%
ATR (14)	12.42
RSI (14)	55.09
Beta	0.62
Rel Volume	0.78
Avg Volume	1.21M
Volume	943,193

Perf Week	-0.49%
Perf Month	0.42%
Perf Quarter	7.39%
Perf Half Y	8.37%
Perf YTD	22.64%
Perf Year	31.22%
Perf 3Y	-6.19%
Perf 5Y	-1.63%
Perf 10Y	221.59%
Recom	1.88
Target Price	479.62
Prev Close	429.48
Price	429.90
Change %	0.10%

Consensus

Buy

Avg. Price Target

$479.62

Implied Upside

+11.6%

Analysts13incl. previous ratings

Rating Distribution6 Buy · 7 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 20, 2026	Upgrade	DDeutsche Bank	Hold → Buy	$498	+15.8%
Apr 29, 2026	Upgrade	BBofA Securities	Neutral → Buy	$435	+1.2%
Apr 08, 2026	Initiated	EEvercore ISI	In-line	$345	-19.7%
Feb 03, 2026	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$358	-16.7%
Jan 08, 2026	Upgrade	WWolfe Research	Peer Perform → Outperform	$425	-1.1%
Dec 19, 2025	Downgrade	DDeutsche Bank	Buy → Hold	$320	-25.6%
Oct 14, 2025	Initiated	GGoldman	Neutral
Jul 21, 2025	Downgrade	AArgus	Buy → Hold
Jul 18, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$310	-27.9%
Apr 15, 2025	Downgrade	RRobert W. Baird	Outperform → Neutral	$529	+23.1%
Mar 17, 2025	Upgrade	AArgus	Hold → Buy	$450	+4.7%
Jan 22, 2025	Downgrade	SStephens	Overweight → Equal-Weight	$520 → $440	+2.3%
Oct 18, 2024	Downgrade	AArgus	Buy → Hold
Jul 18, 2024	Downgrade	BBofA Securities	Buy → Neutral	$646 → $530	+23.3%
Jun 24, 2024	Initiated	MMorgan Stanley	Overweight	$643	+49.6%
May 30, 2024	Initiated	RRobert W. Baird	Outperform	$649	+51.0%
Mar 06, 2024	Initiated	BBarclays	Overweight	$584	+35.8%
Jul 12, 2023	Downgrade	WWolfe Research	Outperform → Peer Perform
Apr 27, 2023	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$500 → $571	+32.8%
Apr 21, 2023	Initiated	CCantor Fitzgerald	Overweight	$547	+27.2%

Nov-04-26 10:06AM	Health insurers, hospitals rally after sweeping midterm win for Democrats (Reuters)
09:14AM	Policy relief sparks surge in health insurance and hospital stocks (Investing.com)
Oct-21-26 04:46PM	2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG (Zacks)
11:06AM	Elevance Health's 41% Beat Leans On Investment Income, But A Higher 2026 Baseline Is The Real Upgrade (Earnings Whispers)
09:53AM	Elevance Health Shares Rise as Third-Quarter Earnings Beat Estimates and 2026 Guidance Increases (InvestorsHub)
07:30AM	Loading…
07:30AM	Elevance Health Names Jeff Park President of Carelon (Business Wire)
07:03AM	Elevance Health Raises Yearly Outlook as Profit, Revenue Rise (The Wall Street Journal)
06:40AM	Elevance Health beats estimates, raises guidance (Investing.com)
06:07AM	Elevance Health: Q3 Earnings Snapshot (Associated Press)
06:00AM	Elevance Tops Earnings Expectations and Lifts Guidance (Barrons.com)
06:00AM	Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance (Business Wire)
Oct-16-26 10:54AM	Where Could UnitedHealth's Next Growth Come From? (Trefis)
Oct-15-26 09:14AM	What Happened With UnitedHealth Stock This Week? (Trefis)
Oct-13-26 06:03AM	UnitedHealth keeps medical costs under control - and raises its outlook again (MarketWatch)
Oct-12-26 03:45PM	Humana leads Managed Care winners in new CMS Star Ratings - Evercore (Investing.com)
09:41AM	Loading…
09:41AM	Salesforce upgraded, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Oct-09-26 09:13AM	Is Clover Health Stock Too Dependent On One Group Of Members? (Trefis)
Oct-05-26 08:00AM	Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026 (Business Wire)
Oct-02-26 04:24AM	How Much Downside Is Left In CVS Health Stock? (Trefis)
Oct-01-26 07:00AM	Elevance Health's Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support (Business Wire)
Sep-30-26 02:39PM	Elevance cracks down on hospital billing for off-campus care (Healthcare Dive)
Sep-29-26 02:25PM	What Are UNH Stock Investors Betting On? (Trefis)
Sep-24-26 12:34PM	What Should CVS Stock Investors Be Watching Now? (Trefis)
Sep-23-26 05:06PM	Liberty HealthShares Dorsey Morrow Makes the Financial Case for Healthsharing on Beckers Healthcare Podcast (Exec Edge)
12:26PM	Did UnitedHealth Name The Fix Before Its Stock Ran? (Trefis)
Sep-22-26 02:09PM	Can UNH Stock Keep Growing Earnings While Its Sales Stall? (Trefis)
Sep-18-26 08:15AM	Should You Buy CVS Stock For The Margin Aetna Is Rebuilding? (Trefis)
Sep-16-26 01:16PM	The One Cost Line UnitedHealth Stock Has Not Caught Up To Yet (Trefis)
Sep-14-26 05:10PM	CVS Stock Returned $24B In Cash: Why Did It Still Lag The Market? (Trefis)
03:41PM	Should You Buy UNH Stock Because Its Cash Runs Ahead Of Its Profit? (Trefis)
09:38AM	Loading…
Sep-11-26 09:38AM	Up 36% in the Last 12 Months, Does Elevance Health Stock Have More Room to Run Through 2028? (TIKR)
Sep-10-26 04:30PM	Elevance Health Inc. stock outperforms competitors on strong trading day (MarketWatch)
03:36PM	Should You Buy Elevance Health Stock For The Margin It Lost? (Trefis)
07:04AM	Elevance Health Inc's Dividend Analysis (GuruFocus.com)
Sep-09-26 03:30PM	Why Is UNH Stock Trading At A Premium With The Slowest Growth? (Trefis)
Sep-03-26 01:35PM	UnitedHealth Stock Recovered Before Its Margins Did (Trefis)
10:45AM	CVS Stock Has Left Its Peers Behind. Or Has It? (Trefis)
Aug-31-26 02:25PM	UNH Stock Gets Cheaper Only If The Margins Come Back (Trefis)
Aug-28-26 02:06PM	Is CVS Stock Set for a Rebound? (Trefis)
Aug-27-26 07:26PM	Can a $68 Billion Payout Save UNH Stock? (Trefis)
Aug-25-26 05:27AM	Elevances behavioral health division nabs new president (Healthcare Dive)
Aug-24-26 01:04PM	UnitedHealth Stock's Biggest Risk Sits In The Commercial Book (Trefis)
Aug-21-26 04:58PM	Is The Pullback In UNH Stock A Glitch Or A Warning? (Trefis)
Aug-13-26 05:50PM	The Signs Before UnitedHealth Stock Ran Were In Its Own Exit Plan (Trefis)
05:14PM	'I didn't know what else to do:' Patients take their health-insurance battles to Facebook and LinkedIn (MarketWatch)
05:09PM	CVS Health Stock's Next Leg Sits In Aetna's Unfinished Margin Repair (Trefis)
Aug-07-26 04:40PM	UNH Leads Its Peer Group. You Pay For That (Trefis)
Aug-05-26 11:50AM	The Case For UnitedHealth Stock Is Margin, Not Growth (Trefis)
Aug-03-26 04:17PM	CVS Health Stock Surged On An Aetna Recovery That Management Had Already Sized (Trefis)
Jul-31-26 10:36AM	UnitedHealth Stock Ran On A Repricing The Company Described In Advance (Trefis)
03:00AM	Elevance Healths CEO started her career as a pro basketball player. Now shes the highestranking woman on the Global 500, leading a $199B giant (Fortune)
Jul-24-26 04:56PM	The Real Price of UnitedHealth Stock Is Two Years Away (Trefis)
Jul-22-26 04:45PM	This Medicaid Insurer's Stock Has Climbed in 2026. Investors Still Have Doubts. (Barrons.com)
Jul-21-26 05:26PM	The Hidden Engine Behind Elevance Health Stock's Next Climb (Trefis)
04:33PM	What Kept Coming Up When Analysts Grilled UNH (Trefis)
Jul-20-26 10:43AM	The Real Risk Inside UnitedHealth Stock (Trefis)
Jul-17-26 06:20PM	Elevance Health CEO Snaps Up Stock After Post-Earnings Slide (Barrons.com)
06:09PM	What A Patient Holder Is Really Paying For CVS Health Stock (Trefis)
06:02PM	What's A Strong Quarter Worth When Elevance Health Is Ditching Its Own Markets? (Trefis)
Jul-16-26 10:54AM	UnitedHealth stock jumps on Q2 earnings, raises full-year outlook (Yahoo Finance Video)
09:19AM	The Medicaid Problem That Swallowed an Earnings Beat (Trefis)
08:30AM	The Medicaid Problem Weighing On Elevance Health Stock (Trefis)
08:30AM	The Real Price of Admission for CVS Health Stock (Trefis)
Jul-15-26 05:00PM	Elevance Health Inc (ELV) Q2 2026 Earnings Call Highlights: Strong EPS Growth and Strategic ... (GuruFocus.com) -8.54%
04:30PM	Elevance Health Inc. stock underperforms Wednesday when compared to competitors (MarketWatch)
09:36AM	Health insurance stocks slide after Elevance highlights margin pressures (ELV) (InvestorsHub)
08:59AM	Why Elevance Earnings Gave Health Insurance Stocks A Cold; UNH Up Next (Investor's Business Daily)
08:29AM	Elevance Health beats second-quarter forecasts but shares slide on margin pressure (ELV) (InvestorsHub)
07:21AM	Insurance stocks fall after Elevance Health results show margin pressure (Investing.com)
06:48AM	Elevance Health beats estimates but shares tumble as margins drop (Investing.com)
06:44AM	Elevance Health Raises Earnings Outlook on Higher Sales (The Wall Street Journal)
06:10AM	Elevance Health: Q2 Earnings Snapshot (Associated Press)
06:00AM	Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance (Business Wire)
Jul-14-26 06:07PM	Elevance Is Overcoming Medicare Advantage Hurdles. Earnings Could Show It. (Barrons.com)
Jul-13-26 01:54PM	The Premium On CVS Stock Vs What Its Peers Deliver (Trefis)
03:00AM	Elevance and UnitedHealth Earnings Are Next Test for Hot Health Insurer Stocks (Barrons.com)
Jul-10-26 07:55AM	UNH Showered Owners With Cash. The Stock Did Not Cooperate (Trefis)
Jul-09-26 09:47AM	The Real Price Of UnitedHealth Stock Isn't On Today's Label (Trefis)
Jul-06-26 04:30PM	Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026 (Business Wire)
12:11PM	What CVS Health Stock Was Telling You About Its Three-Dollar Earnings Prize (Trefis)
Jul-03-26 08:20AM	The Unpopular Move That Telegraphed the Elevance Health Stock Surge (Trefis)
Jul-02-26 10:46AM	Elevance sues CMS after Medicare Advantage stars recalculation (Healthcare Dive)
Jul-01-26 04:30PM	Elevance Health Inc. stock outperforms competitors on strong trading day (MarketWatch) +7.62%
Jun-30-26 08:49AM	Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) (InvestorsHub)
Jun-17-26 10:00AM	Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide (Business Wire)
05:30AM	The Medicare Crisis for Insurers Is Over. The Easy Gains Are Too. (The Wall Street Journal)
Jun-16-26 11:44AM	Why Did UnitedHealth Stock Choose Pain Over Growth? (Trefis)
Jun-05-26 04:20PM	Can UNH Stock Sustain Its Recent 40% Rally? (Trefis)
Jun-04-26 12:38PM	UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. (Barrons.com)
Jun-01-26 04:54AM	Elevance again avoids Medicare Advantage sanctions, but threat remains (Healthcare Dive)
May-20-26 09:43AM	Cigna downgraded, Humana upgraded: Wall Street's top analyst calls (The Fly)
09:35AM	Deutsche Bank sees new upswing for health insurers after years of margin pressure (Investing.com)
May-04-26 02:10PM	Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care (Business Wire)
Apr-30-26 08:00AM	Elevance Healths Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses (Business Wire)
Apr-29-26 02:06PM	Elevance Health and 2 More Stocks to Buy. Better Days Are Ahead for Medicaid Providers. (Barrons.com)
07:34AM	Analysts upgrade Elevance, Centene shares as Medicaid margins expected to recover (Investing.com)
Apr-23-26 08:03AM	Molina controls costs in Q1 but future Medicaid spending in doubt (Healthcare Dive) +5.51%
03:02AM	Elevance Health Inc (ELV) Q1 2026 Earnings Call Highlights: Strong EPS Growth and Raised Guidance (GuruFocus.com)
Apr-22-26 07:55AM	Elevance perks up in 2026 though Medicare Advantage payout could ding profits (Healthcare Dive)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAVU RATNAKAR	EVP & Chief Digital Info Ofr	Nov 05 '26	Sale	440.00	1,300	572,000	14,849	Nov 06 04:32 PM
RATNAKAR LAVU	Officer	Nov 05 '26	Proposed Sale	440.00	1,300	572,000		Nov 05 04:13 PM
Kaye Mark	EVP & CFO	Oct 22 '26	Sale	440.13	10,584	4,658,357	19,919	Oct 23 04:30 PM
MARK B KAYE	Officer	Oct 22 '26	Proposed Sale	440.13	10,584	4,658,378		Oct 22 04:03 PM
PERU RAMIRO G	Director	Jul 17 '26	Buy	366.05	1,000	366,050	10,908	Jul 17 03:04 PM
BOUDREAUX GAIL	President and CEO	Jul 17 '26	Buy	367.79	2,725	1,002,230	171,976	Jul 17 01:50 PM
CLARK R KERRY	Director	Jul 07 '26	Proposed Sale	419.91	1,500	629,865		Jul 07 04:58 PM
Penczek Ronald W	CAO & Controller	Jun 12 '26	Sale	403.16	369	148,766	3,740	Jun 15 04:10 PM
RONALD WILLIAM PENCZEK	Officer	Jun 12 '26	Proposed Sale	403.16	369	148,767		Jun 12 05:27 PM
Dixon Robert L JR	Director	Jun 11 '26	Sale	401.77	151	60,667	10,734	Jun 12 04:12 PM
Dixon Robert L JR	Director	Jun 11 '26	Proposed Sale	401.76	151	60,666		Jun 11 05:10 PM
Penczek Ronald W	CAO & Controller	May 19 '26	Option Exercise	294.30	1,531	450,579	5,640	May 20 04:11 PM
Penczek Ronald W	CAO & Controller	May 19 '26	Sale	403.13	1,531	617,192	4,109	May 20 04:11 PM
RONALD WILLIAM PENCZEK	Officer	May 19 '26	Proposed Sale	403.13	1,531	617,192		May 19 04:25 PM
SCHULMAN AMY W	Director	Mar 12 '26	Sale	287.50	26	7,475	218	Mar 23 04:10 PM
Kendrick Charles Morgan JR	EVP & President, Commercial	Mar 06 '26	Sale	284.92	3,196	910,604	11,791	Mar 09 04:45 PM
CHARLES MORGAN KENDRICK	Officer	Mar 06 '26	Proposed Sale	284.92	3,196	910,593		Mar 06 04:17 PM
COLLIS STEVEN H	Director	Mar 05 '26	Buy	289.84	3,000	869,520	3,639	Mar 06 08:03 AM

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

PresidentMs. Gail Koziara Boudreaux

Executive VP & CFOMr. Mark Bradley Kaye

Special AdvisorMr. Peter David Haytaian Esq.

EVP and President of Commercial & Specialty Health BenefitsMr. Charles Morgan Kendrick Jr.

Executive VP & Chief Health Benefits OfficerMs. Felicia Farr Norwood

Open in Screener

GUTS

Fractyl Health Inc

0.8121

Nov 12 • 3:59 PM ET -0.0691 (-7.84%)

0.8501

Aftermarket • 7:25 PM ET +0.0380 (4.68%)

Healthcare Biotechnology USA Nano NASD

GUTS Fractyl Health Inc daily Stock Chart

Peers: BMEA AARD ALT SKYE GPCR MBX VKTX LXRX RYTM BIOA

| Held by: VTI VXF

Index	-
Market Cap	10.77M
Enterprise Value	24.37M
Income	-105.65M
Sales	0.00M
Book/sh	-0.13
Cash/sh	3.55
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	100
IPO	Feb 02, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	0.23
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.15
Current Ratio	3.15
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-13.12
EPS next Y	-5.61
EPS next Q	-1.24
EPS this Y	81.50%
EPS next Y	-35.82%
EPS next 5Y	42.51%
EPS past 3/5Y	-11.62% -16.69%
Sales past 3/5Y	- -
EPS Y/Y TTM	46.66%
Sales Y/Y TTM	-100.00%
EPS Q/Q	71.69%
Sales Q/Q	-
Earnings	Nov 12 AMC
EPS/Sales Surpr.	28.78% -

Insider Own	15.01%
Insider Trans	13.45%
Inst Own	38.06%
Inst Trans	-3.37%
ROA	-146.75%
ROE	-778.33%
ROIC	-196.04%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-20.65%
SMA50	-79.90%
SMA200	-88.13%
Trades

Shs Outstand	13.22M
Shs Float	11.27M
Short Float	5.19%
Short Ratio	1.24
Short Interest	0.59M
52W High	29.34 -97.23%
52W Low	0.80 1.50%
Volatility	10.23% 13.92%
ATR (14)	0.25
RSI (14)	20.20
Beta	2.89
Rel Volume	0.37
Avg Volume	472.47K
Volume	174,791

Perf Week	-9.34%
Perf Month	-80.10%
Perf Quarter	-90.05%
Perf Half Y	-92.91%
Perf YTD	-96.92%
Perf Year	-94.01%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	41.00
Prev Close	0.88
Price	0.81
Change %	-7.84%

Consensus

Strong Buy

Avg. Price Target

$41.00

Implied Upside

+4,948.6%

Analysts5incl. previous ratings

Rating Distribution4 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 30, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$2	+146.3%
Sep 15, 2025	Initiated	HH.C. Wainwright	Buy	$9	+1,008.2%
Aug 28, 2025	Initiated	LLadenburg Thalmann	Buy	$3.60	+343.3%
Feb 28, 2024	Initiated	EEvercore ISI	Outperform
Feb 27, 2024	Initiated	MMorgan Stanley	Overweight	$18	+2,116.5%
Feb 27, 2024	Initiated	BBofA Securities	Buy	$26	+3,101.6%

Nov-12-26 06:48PM	Fractyl Health Beats On A Smaller Loss As Revita Clears Its Pivotal Hurdle, But A Shrinking Balance Sheet Leaves Little Room For Error (Earnings Whispers) -7.84%
04:05PM	Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Nov-07-26 08:42AM	Fractyl Health's Q3 Report Becomes A Test Of Cash And Credibility After An 88% Collapse (Earnings Whispers)
Nov-06-26 07:00AM	Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026 (GlobeNewswire)
Oct-30-26 07:00AM	Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization (GlobeNewswire)
07:00AM	Loading…
Oct-29-26 07:00AM	Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance (GlobeNewswire) +11.40%
Oct-22-26 07:00AM	Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance (GlobeNewswire)
Oct-16-26 09:32AM	Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans (InvestorsHub) -62.74%
07:00AM	Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation (GlobeNewswire)
Sep-29-26 08:56PM	Robbins LLP is Investigating Allegations that Fractyl Health, Inc. Misled Investors Regarding the Viability and Efficacy of its Revita DMR System (Newsfile) +10.40%
Sep-16-26 07:33PM	GUTS Stockholders Have Rights - If you Lost Money Investing in Fractyl Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire) +5.03%
Sep-09-26 07:00AM	Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire) -6.60%
Sep-03-26 10:40AM	Did You Lose Money Investing in Fractyl Health, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against GUTS (Newsfile)
Sep-01-26 08:56AM	Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day (InvestorsHub)
Aug-20-26 07:00AM	Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita, a Procedural Therapy for Post-GLP-1 Weight Maintenance (GlobeNewswire)
01:03AM	Loading…
Aug-11-26 01:03AM	Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ... (GuruFocus.com)
Aug-10-26 04:05PM	Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Aug-03-26 04:05PM	Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026 (GlobeNewswire)
Jul-22-26 04:01PM	Fractyl Health to Participate in Upcoming Investor Events (GlobeNewswire)
Jul-15-26 06:00AM	Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation (GlobeNewswire) +13.75%
Jun-04-26 07:00AM	Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure (GlobeNewswire)
Jun-01-26 07:00AM	Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy (GlobeNewswire) +7.57%
May-13-26 01:02AM	Fractyl Health Inc (GUTS) Q1 2026 Earnings Call Highlights: Pivotal Trial Progress and ... (GuruFocus.com) +29.20%
May-12-26 04:05PM	Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
May-11-26 07:00AM	Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes (GlobeNewswire)
06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive)
May-05-26 07:00AM	Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference (GlobeNewswire)
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire) -5.20%
Mar-24-26 11:01PM	Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) +16.17%
04:01PM	Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire)
07:00AM	Loading…
Mar-17-26 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 (GlobeNewswire)
Feb-26-26 07:00AM	Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita for Post-GLP-1 Weight Maintenance (GlobeNewswire) -6.19%
Feb-23-26 09:35AM	Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-29-26 01:48PM	Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product (Benzinga) -68.04%
12:12PM	Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain (MarketBeat)
07:00AM	Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita After GLP-1 Discontinuation (GlobeNewswire)
Jan-06-26 07:00AM	Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness (GlobeNewswire)
Jan-05-26 07:00AM	Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category (GlobeNewswire) -8.44%
Jan-03-26 06:19AM	Analysts Keep Buy Ratings on Fractyl Health (GUTS) (Insider Monkey)
Dec-31-25 11:12AM	Fractyl Health's REVEAL-1 Study Shows Positive Six-Month Results for Revita in Maintaining Weight and Glycemic Control Post-GLP-1 Use (Insider Monkey)
Dec-15-25 05:45PM	Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones (GlobeNewswire)
Dec-02-25 07:00AM	Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure (GlobeNewswire) +17.95%
Dec-01-25 07:00AM	Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-13-25 12:01AM	Fractyl Health Inc (GUTS) Q3 2025 Earnings Call Highlights: Pioneering Weight Loss Solutions ... (GuruFocus.com)
Nov-12-25 04:05PM	Fractyl Health Reports Third Quarter 2025 Results; Revita Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 (GlobeNewswire)
Nov-05-25 07:00AM	Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 (GlobeNewswire)
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Oct-17-25 09:59AM	Fractyl Health Unveils Potent Preclinical Data for Dual GIP/GLP-1 Gene Therapy RJVA-002 for Obesity (Insider Monkey)
Oct-07-25 07:00AM	Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity (GlobeNewswire) -6.80%
Sep-26-25 07:05AM	Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock (GlobeNewswire) +32.67%
07:00AM	Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation (GlobeNewswire)
Sep-03-25 07:00AM	Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth (GlobeNewswire)
Aug-13-25 03:12AM	Fractyl Health Inc (GUTS) Q2 2025 Earnings Call Highlights: Financial Discipline and Promising ... (GuruFocus.com)
Aug-12-25 04:05PM	Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-07-25 04:05PM	Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-06-25 04:05PM	Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -45.99%
08:30AM	Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering (GlobeNewswire)
Aug-05-25 04:15PM	Fractyl Health Announces Proposed Public Offering (GlobeNewswire)
04:02PM	Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure (GlobeNewswire)
Jul-29-25 10:23AM	Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS) (Insider Monkey) -7.61%
Jun-23-25 07:40AM	Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy (GlobeNewswire) -24.77%
07:30AM	Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models (GlobeNewswire)
Jun-18-25 07:00AM	Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing (GlobeNewswire)
Jun-13-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.07%
07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire)
Jun-04-25 07:00AM	Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide (GlobeNewswire)
May-19-25 07:00AM	Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes (GlobeNewswire) +25.44%
May-17-25 07:15AM	Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 (GlobeNewswire)
May-13-25 04:05PM	Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -13.28%
May-06-25 07:00AM	Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -7.98%
Apr-28-25 04:30PM	Fractyl Health to Present Compelling Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire) +5.00%
Apr-02-25 03:34PM	Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025 (Insider Monkey)
Apr-01-25 07:00AM	Fractyl Health Reports Positive Early Data Showing Revita Has Potential to Prevent Weight Regain After GLP-1 Discontinuation (GlobeNewswire) -6.72%
Mar-03-25 04:05PM	Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Feb-24-25 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 (GlobeNewswire)
Feb-12-25 09:35AM	After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS) (Zacks)
Feb-10-25 03:00AM	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments (Pharma Voice)
Jan-31-25 08:01AM	Fractyl Health Announces Increased Focus on Groundbreaking Revita Weight Maintenance and Rejuva Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 (GlobeNewswire) -5.15%
Jan-13-25 07:00AM	Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort (GlobeNewswire) +5.41%
Jan-06-25 09:10AM	Heres Why Fractyl Health, Inc. (NASDAQ:GUTS) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) -6.36%
Dec-12-24 07:00AM	Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-09-24 07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Nov-26-24 07:00AM	Fractyl Health to Participate in the Upcoming December Conferences (GlobeNewswire)
Nov-12-24 04:05PM	Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-24 04:05PM	Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek 2024 (GlobeNewswire) -9.86% -6.25%
07:00AM	Fractyl Health Presented New Analysis from Pooled Data of Revita Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek 2024 (GlobeNewswire)
Oct-29-24 07:00AM	Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 (GlobeNewswire) +23.19%
Oct-28-24 07:00AM	Fractyl Health to Present Compelling Weight Maintenance Data from both Revita and Rejuva Platforms at ObesityWeek 2024 (GlobeNewswire) +16.46%
Sep-24-24 07:00AM	Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-03-24 07:00AM	Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.38%
Aug-12-24 10:53AM	Rising diabetes rates spur growth in weight management solutions (Medical Device Network) +14.61%
Aug-08-24 12:13PM	Fractyl Health touts positive year-long weight loss results for Revita device (Clinical Trials Arena) -6.19%
08:00AM	Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure (GlobeNewswire)
Aug-07-24 07:00AM	Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 (GlobeNewswire) -9.77%
Jul-30-24 07:00AM	Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs (GlobeNewswire)
Jun-25-24 09:02AM	FDA expands Fractyl endoscopy trial to include untreated diabetes patients (Medical Device Network) -9.22%
07:00AM	Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day (GlobeNewswire)
Jun-24-24 06:00AM	Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates (GlobeNewswire) +5.76%
Jun-23-24 01:30PM	Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BRADLEY WILLIAM	Director	Sep 14 '26	Buy	0.62	64,516	39,903	149,138	Sep 16 04:05 PM
Royan Ajay	Director	Jun 12 '26	Buy	0.85	23,000	19,596	40,901	Jun 15 06:06 PM
BRADLEY WILLIAM	Director	Jun 10 '26	Buy	0.73	68,493	50,329	84,622	Jun 11 05:04 PM
Sheffield Ian	Director	Jun 10 '26	Buy	0.73	35,000	25,529	35,000	Jun 11 05:00 PM
Rajagopalan Harith	Chief Executive Officer	Jun 10 '26	Buy	0.73	25,000	18,252	540,557	Jun 11 04:59 PM
Smith Weber Lara	Chief Financial Officer	Jun 08 '26	Buy	0.69	20,000	13,708	20,000	Jun 09 06:55 PM
Rajagopalan Harith	Chief Executive Officer	Dec 04 '25	Buy	1.92	10,416	19,999	501,745	Dec 08 07:05 AM

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Ph.D.Dr. Harith Rajagopalan M.D.

General Counsel & Corporate SecretaryMs. Sarah S. Toomey Esq.

CFO & TreasurerMs. Lara Smith Weber

Head of Investor Relations & Corporate DevelopmentMr. Brian Luque

Senior Vice President of RegulatoryMr. Jon Fitzgerald

All the Features.Half the Price.

ALNY

Alnylam Pharmaceuticals Inc

ELV

Elevance Health Inc

GUTS

Fractyl Health Inc

Upgrade your Finviz experience

All the Features.
Half the Price.